Time: 2024-12-04
Melioidosis, a deadly bacterial infection, airs significant challenge globally due to its high mortality rate and resistance to treatment. However, research_worker at Princeton Chemistry's Seyedsayamdost Lab have make significant pace in battle this neglect tropical disease by development a new treatment approach that target the pathogen with low-dose antibiotic while continue the intestine microbiome.
The groundbreaking research conduct by the Seyedsayamdost Lab focus on identify the metabolic vulnerability of the pathogen that cause melioidosis. By use low-dose antibiotic, the research_worker were able to target particular nerve_pathway in the pathogen's metamorphosis, lead to a discovery in battle this challenge disease. This advanced approach hour_angle the potential to revolutionize antibiotic development and pave the manner for novel treatment for a wide scope of infectious diseases.
Through the use of High Throughput Elicitor Screening ( HiTES ), the research_worker were able to uncover critical penetration into the pathogen's metamorphosis when expose to low-dose antibiotic. This in-depth analysis uncover a previously unknown metabolite stress response that could be target to suppress the pathogen's survival. By combining trimethoprim with a natural merchandise, dehydrocostus lactone ( DHL ), the research_worker successfully interrupt the function of a key enzyme in the pathogen, lead to its selective eradication without harm necessity intestine bacteria.
The promise consequence of this research widen beyond melioidosis and open up new possibility for development target treatment for a assortment of pathogen. By leverage the alone metabolic vulnerability of infectious agent, research_worker can potentially revolutionize the field of antibiotic development and combat the growth menace of disinfectant resistance. This advanced approach highlight the importance of interdisciplinary collaboration and thinking outside traditional boundary in science to address press global health challenges.